CRDF logo

CRDF
Cardiff Oncology Inc

18,749
Mkt Cap
$117.59M
Volume
572.00
52W High
$4.56
52W Low
$1.48
PE Ratio
-2.51
CRDF Fundamentals
Price
$1.72
Prev Close
$1.72
Open
$1.72
50D MA
$1.74
Beta
1.50
Avg. Volume
599,040.97
EPS (Annual)
-$0.6864
P/B
2.59
Rev/Employee
$19,129.03
$130.35
Loading...
Loading...
News
all
press releases
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has ass...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Trading Down 1.1% - Here's What Happened
Cardiff Oncology (NASDAQ:CRDF) Stock Price Down 1.1% - Here's Why...
MarketBeat·7d ago
News Placeholder
Noble Financial Issues Optimistic Estimate for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Research analysts at Noble Financial raised their Q1 2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a note issued to...
MarketBeat·29d ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company's investigational PLK1 inhibitor onvansertib during a webinar focused...
MarketBeat·1mo ago
News Placeholder
What is Zacks Research's Forecast for CRDF FY2027 Earnings?
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Investment analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a note issued to investors on Monday, March 2nd...
MarketBeat·2mo ago
News Placeholder
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Cardiff Oncology from a "sell" rating to a "hold" rating in a research note on Wednesday...
MarketBeat·2mo ago
News Placeholder
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One research analyst...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Issues Optimistic Outlook for CRDF Earnings
Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Cardiff Oncology in a note issued to investors on Wednesday...
MarketBeat·2mo ago
News Placeholder
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly...
MarketBeat·2mo ago
<
1
2
...
>

Latest CRDF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.